Search results
Showing 1861 to 1867 of 1867 results for do not do
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
Learn more about NICE's new guideline on identifying and managing adrenal insufficiency
adrenal insufficiency, a rare condition which occurs when the adrenal glands do not produce enough essential hormones – particularly...
Process manual for the endorsement of guidance and quality standard support resources (PMG29)
The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.
This guide has been updated and replaced by practical steps to improving the quality of care and services using NICE guidance.
This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
Computerised cognitive behaviour therapy for depression and anxiety (TA97)
The guidance was withdrawn in July 2018 to allow OCFighter to be considered for an improving access to psychological therapies assessment briefing. If OCFighter is not selected, it may be considered for a medtech innovation briefing.